Therapy Acceleration Program
Therapy Acceleration Program
Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors
Krakow, Poland – August 25, 2021 – Ryvu Therapeutics (WSE:RVU) announced today that the first patient enrolled in the Phase I/II clinical trial investigating RVU120 (SEL120) in relapsed/refractory metastatic or advanced solid tumors, has received the first dose of the study drug.
RVU120 is a highly selective first-in-class CDK8/CDK19 inhibitor, which has demonstrated efficacy in a number of solid tumors in in vitro and in vivo models as well as in hematologic malignancies.
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform
Waltham, Mass., August 18, 2021 – Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP).
Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2
PALO ALTO, CA, August 12, 2021 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for IO-108, a novel antagonist antibody targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4) for the treatment of solid tumors.
X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials
BOSTON, Aug. 03, 2021 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today reported financial results for the second quarter and six months ended June 30, 2021. The company also announced key enrollment milestone achievements for its lead product candidate, mavorixafor, a novel, oral small molecule currently being evaluated in a Phase 3 clinical trial (4WHIM) for patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and in two Phase 1b clinical trials for patients with Waldenström’s macroglobulinemia and Severe Congenital Neutropenia (SCN) and chronic neutropenia disorders, respectively.
BERKELEY, CA - Jul. 27, 2021 - Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share. The aggregate gross proceeds to Caribou from the offering were approximately $304.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Caribou. The shares began trading on the Nasdaq Global Select Market on July 23, 2021, under the ticker symbol “CRBU.”
Planegg/Munich, Germany, July 15, 2021 - MorphoSys announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. for a total equity value of the transaction of approximately $1.7 billion. MorphoSys will promptly complete its acquisition of Constellation through a second step merger of MorphoSys Development Inc. with and into Constellation resulting in Constellation surviving as an indirect wholly owned subsidiary of MorphoSys.
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy
BERKELEY, CA – July 12, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial (NCT04637763) to evaluate the company’s lead product candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells that have been engineered using Caribou’s chRDNA technology to reduce the risk of graft versus host disease (GvHD) and knock out PD-1 to boost the persistence of CAR-T cell antitumor activity.
WATERTOWN, Mass., July 06, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten public offering at a public offering price of $47.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $257.0 million.
SAN DIEGO, June 24, 2021 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1b portion of KOMET-001, a Phase 1/2 clinical trial of the Company’s oral, potent and selective menin inhibitor, KO-539, in patients with relapsed or refractory acute myeloid leukemia (AML).
Current and former TAP partners presented new data during the virtual 2021 European Hematology Association (EHA) meeting that took place from June 11-17th.
Current and former TAP partners presented new data during the virtual 2021 American Society of Clinical Oncology (ASCO) meeting that took place from June 4-8th.
PLANEGG/MUNICH, Germany & CAMBRIDGE, Mass. Jun. 2, 2021- MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) today announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.
In honor of Asian American and Pacific Islander Heritage Month in May, LLS is highlighting the stories of volunteers, healthcare professionals, researchers, patients, survivors, and advocates from across our community. Recently, we caught up with Charlene Liao, Ph.D., Co-Founder, President, and CEO of Immune-Onc Therapeutics, a new LLS Therapy Acceleration Program® (LLS TAP) partner.
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
SAN DIEGO, May 20, 2021 - BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving cancer medicines, today announced a $92 million Series E financing. The proceeds from the financing will be used to advance multiple molecular glues, PHM-based PROTACs and monovalent degraders, including BTX-1188, toward clinical development. BioTheryX also plans to advance the clinical development of its lead multi-kinase inhibitor, BTX-A51, for the treatment of acute myeloid leukemia, myelodysplastic syndromes and solid tumors.
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells
Heidelberg, Germany, May 13, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company announced today the publication of preclinical in vitro and in vivo research of its lead innate cell engager (ICE®), AFM13 (CD16A/CD30), combined with healthy donor-derived NK cells in Clinical Cancer Research, and supports use of AFM13 combined with NK cells as a promising therapy for CD30-positive hematological malignancies.
RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.
Immune-Onc Receives California Institute for Regenerative Medicine Award to Conduct Clinical Trial in AML
Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $6.0 million to Immune-Onc Therapeutics to conduct a clinical trial for patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML).
WATERTOWN, Mass., April 19, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Boston Business Journal (BBJ) has named Kymera Therapeutics to its 2021 Best Places to Work, an exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people.
April 16, 2021 - Sanofi and Kiadis announce today the successful completion of Sanofi’s acquisition of Kiadis, a clinical-stage biopharmaceutical company developing next generation, ‘off-the-shelf’, NK cell-therapies.
Current and former TAP partners show off data during the virtual 2021 American Association for Cancer Research (AACR) meeting that took place from April 10-15th.
DUBLIN, March 30, 2021 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos® (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged one year and older.
Immune-Onc Therapeutics Announces $73 Million Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors
PALO ALTO, CA, March 30, 2021 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing. The round was led by Oceanpine Capital and the company also received a strategic capital investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP), directed toward advancing the company’s work to treat blood cancers.
CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages
PHILADELPHIA, March 18, 2021 - CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company spun out of the University of Pennsylvania (Penn) and focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in the Phase 1 multi-center clinical trial for CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M).
March 16, 2021 - CPX-351 (Vyxeos, daunorubicin and cytarabine liposome for injection) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine approved by the US Food and Drug Administration in 2017 and the European Medicines Agency in 2018 for the treatment of adults with newly diagnosed t-AML or AML with myelodysplasia-related changes (AML-MRC). In the primary analysis of data from the pivotal randomized phase 3 study in older adults with newly diagnosed high-risk/sAML, induction followed by consolidation with CPX-351 demonstrated a significantly improved median overall survival. After 5 years of follow-up, survival benefit was maintained.
Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis
Heidelberg, Germany, March 10, 2021 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its decision to continue enrollment in the REDIRECT trial (NCT04101331), which is evaluating AFM13 as a monotherapy for the treatment of patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL).
February 26, 2021 - Congrats to new TAP partner, Immune-Onc for being featured in BioCentury as an Emerging Company.
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
Berkeley, CA, March 3, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced the successful completion of an oversubscribed $115 million Series C financing including a strategic investment by The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of allogeneic immune cell therapies for oncology with a major focus on blood cancers.
PHILADELPHIA, March 1, 2021 - CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA's total capital raised to date to nearly $121 million. The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program® (TAP) also participated in the second closing of Carisma's Series B equity financing to support one or more CAR macrophage cell therapy programs for hematological malignancies.
Kymera Therapeutics Initiates Dosing in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader
WATERTOWN, Mass., March 02, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that the Company recently initiated dosing of the Phase 1 clinical trial evaluating KT-474 in adult healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa. KT-474 is a potential first-in-class, highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases and potentially other indications.
GAITHERSBURG, Md., Feb. 17, 2021 - NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response, announced the closing of its previously announced upsized initial public offering where the gross proceeds to NexImmune from the offering were approximately $126.5 million.
This is the first time LLS has participated in an initial public offering through an investment with our Therapy Acceleration Program® (TAP) venture philanthropy initiative.
European Commission Approves ELZONRIS for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
FLORENCE, January 21, 2021 – The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the European Commission (EC) has granted a marketing authorization, for ELZONRIS (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive hematologic malignancy with dismal outcomes.